Kindlin-2 interacts with and stabilizes EGFR and is required for EGF-induced breast cancer cell migration

Cancer Letters

Volumn 361, Issue 2, 2015, Pages 271-281

  Guo, Baohui ^a,b   Gao, Jianchao ^a,b   Zhan, Jun ^a,b   Zhang, Hongquan ^a,b  

^a Department of Biochemistry and Molecular BiologyCancer Hospital of Peking University   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Breast cancer; Cell migration; Epidermal growth factor receptor; Kindlin 2; Protein degradation

Indexed keywords

CELL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; INTEGRIN; KINDLIN 2; MESSENGER RNA; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR; MEMBRANE PROTEIN; MIG2B PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; TUMOR PROTEIN;

ARTICLE; BINDING AFFINITY; BINDING SITE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CELL LEVEL; CELL MIGRATION; CONTROLLED STUDY; CYTOPLASM; DISEASE ACTIVITY; ENZYME STRUCTURE; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; UBIQUITINATION; BREAST TUMOR; CELL MOTION; CELL PROLIFERATION; CONFOCAL MICROSCOPY; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; HELA CELL LINE; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EPIDERMAL GROWTH FACTOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HELA CELLS; HUMANS; MEMBRANE PROTEINS; MICROSCOPY, CONFOCAL; NEOPLASM PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84926123925     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.03.011     Document Type: Article

References (46)

1. Siegel R., et al. Cancer statistics, 2014. CA Cancer J. Clin 2014, 64(1):9-29.
2. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 2012, 490(7418):61-70.
3. Perou C.M., et al. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752.
4. Solomayer E.F., et al. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res. Treat 2000, 59(3):271-278.
5. van 't Veer L.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415(6871):530-536.
6. Smid M., et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008, 68(9):3108-3114.
7. Nielsen T.O., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res 2004, 10(16):5367-5374.
8. Lemmon M.A., Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010, 141(7):1117-1134.
9. Normanno N., et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006, 366(1):2-16.
10. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur. J. Cancer 2001, 37(Suppl. 4):S3-S8.
11. Giltnane J.M., et al. Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort. Cancer 2009, 115(11):2400-2409.
12. De Luca A., et al. The role of the EGFR signaling in tumor microenvironment. J. Cell. Physiol 2008, 214(3):559-567.
13. Rimawi M.F., et al. Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer 2010, 116(5):1234-1242.
14. Viale G., et al. Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res. Treat 2009, 116(2):317-328.
15. Badovinac-Crnjevic T., et al. Significance of epidermal growth factor receptor expression in breast cancer. Med. Oncol 2011, 28(Suppl. 1):S121-S128.
16. Lo H.W., et al. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res 2005, 65(1):338-348.
17. Nicholson R.I., Gee J.M., Harper M.E. EGFR and cancer prognosis. Eur. J. Cancer 2001, 37(Suppl. 4):S9-S15.
18. Warren C.M., Landgraf R. Signaling through ERBB receptors: multiple layers of diversity and control. Cell. Signal 2006, 18(7):923-933.
19. Citri A., Yarden Y. EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell Biol 2006, 7(7):505-516.
20. Ferguson K.M. Structure-based view of epidermal growth factor receptor regulation. Annu. Rev. Biophys 2008, 37:353-373.
21. Ma Y.Q., et al. Kindlin-2 (Mig-2): a co-activator of3 integrins. J. Cell Biol 2008, 181(3):439-446.
22. Montanez E., et al. Kindlin-2 controls bidirectional signaling of integrins. Genes Dev 2008, 22(10):1325-1330.
23. Qu H., et al. Kindlin-2 regulates podocyte adhesion and fibronectin matrix deposition through interactions with phosphoinositides and integrins. J. Cell Sci 2011, 124(Pt 6):879-891.
24. Gao J., et al. A feedback regulation between Kindlin-2 and GLI1 in prostate cancer cells. FEBS Lett 2013, 587(6):631-638.
25. Zhao T., et al. Kindlin-2 promotes genome instability in breast cancer cells. Cancer Lett 2013, 330(2):208-216.
26. Yu Y., et al. Kindlin 2 promotes breast cancer invasion via epigenetic silencing of the microRNA200 gene family. Int. J. Cancer 2013, 133(6):1368-1379.
27. Yu Y., et al. Kindlin 2 forms a transcriptional complex with beta-catenin and TCF4 to enhance Wnt signalling. EMBO Rep 2012, 13(8):750-758.
28. Gkretsi V., et al. Mitogen-inducible Gene-2 (MIG2) and migfilin expression is reduced in samples of human breast cancer. Anticancer Res 2013, 33(5):1977-1981.
29. Wick M., et al. Identification of serum-inducible genes: different patterns of gene regulation during G0→S and G1→S progression. J. Cell Sci 1994, 107(Pt 1):227-239.
30. Lai-Cheong J.E., et al. Colocalization of kindlin-1, kindlin-2, and migfilin at keratinocyte focal adhesion and relevance to the pathophysiology of Kindler syndrome. J. Invest. Dermatol 2008, 128(9):2156-2165.
31. Levkowitz G., et al. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol. Cell 1999, 4(6):1029-1040.
32. Nannuru K.C., Singh R.K. Tumor-stromal interactions in bone metastasis. Curr. Osteoporos. Rep 2010, 8(2):105-113.
33. Cui X., et al. Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH(2)-terminal kinase/activator protein-1 signaling to regulate cell migration. Cancer Res 2006, 66(10):5304-5313.
34. Burness M.L., Grushko T.A., Olopade O.I. Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker?. Cancer J. 2010, 16(1):23-32.
35. Du W.W., et al. Versican G3 promotes mouse mammary tumor cell growth, migration, and metastasis by influencing EGF receptor signaling. PLoS ONE 2010, 5(11):e13828.
36. Nie F., et al. Involvement of epidermal growth factor receptor overexpression in the promotion of breast cancer brain metastasis. Cancer 2012, 118(21):5198-5209.
37. Sin S., et al. Role of the focal adhesion protein kindlin-1 in breast cancer growth and lung metastasis. J. Natl. Cancer Inst 2011, 103(17):1323-1337.
38. Sossey-Alaoui K., et al. Kindlin-3 enhances breast cancer progression and metastasis by activating Twist-mediated angiogenesis. FASEB J. 2014, 28(5):2260-2271.
39. Wei X., et al. Kindlin-2 mediates activation of TGF-beta/Smad signaling and renal fibrosis. J. Am. Soc. Nephrol 2013, 24(9):1387-1398.
40. An Z., et al. Kindlin-2 is expressed in malignant mesothelioma and is required for tumor cell adhesion and migration. Int. J. Cancer 2010, 127(9):1999-2008.
41. Zhan J., et al. Kindlin-2 induced by TGF-beta signaling promotes pancreatic ductal adenocarcinoma progression through downregulation of transcriptional factor HOXB9. Cancer Lett 2015, (361):75-85.
42. Zhan J., et al. Kindlin-2 expression in adult tissues correlates with their embryonic origins. Sci. China Life Sci 2014, 57(7):690-697.
43. Gozgit J.M., et al. Use of an aggressive MCF-7 cell line variant, TMX2-28, to study cell invasion in breast cancer. Mol. Cancer Res 2006, 4(12):905-913.
44. Verbeek B.S., et al. Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. FEBS Lett 1998, 425(1):145-150.
45. Sebastian S., et al. The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim. Biophys. Acta 2006, 1766(1):120-139.
46. Margadant C., et al. Distinct roles of talin and kindlin in regulating integrin α5β1 function and trafficking. Curr. Biol 2012, 22(17):1554-1563.